Rituximab biosimilar - Genor Biopharma

Drug Profile

Rituximab biosimilar - Genor Biopharma

Alternative Names: GB-241

Latest Information Update: 03 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genor Biopharma
  • Developer Genor Biopharma; Nanjing Yoko Biomedical
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma
  • Preclinical Cancer

Most Recent Events

  • 01 Oct 2016 Phase-I clinical trials in Non-Hodgkin's lymphoma in China (Parenteral) (NCT03003039)
  • 19 Sep 2016 China Food and Drug Administration approves IND application for rituximab biosimilar
  • 25 May 2015 Preclinical trials in Cancer in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top